Opus Genetics (IRD) Shares Outstanding (Weighted Average) (2010 - 2026)

Opus Genetics (IRD) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $86.9 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $86.9 million, up 156.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.9 million (up 156.43% YoY), and the FY2025 annual result was $62.2 million, up 3944.42% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $86.9 million in Q1 2026 per IRD's latest filing, from $62.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $86.9 million in Q1 2026 and troughed at $63734.0 in Q2 2022.
• A 5-year average of $28.8 million and a median of $21.0 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) tumbled 95.86% in 2022, then soared 32786.38% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $19.9 million in 2022, then advanced by 5.95% to $21.1 million in 2023, then climbed by 26.51% to $26.7 million in 2024, then surged by 132.91% to $62.2 million in 2025, then jumped by 39.65% to $86.9 million in 2026.
• Business Quant data shows IRD's Shares Outstanding (Weighted Average) at $86.9 million in Q1 2026, $62.2 million in Q4 2025, and $56.1 million in Q3 2025.